Hepatitis C virus resistance to interferon therapy: an alarming situation

2014 ◽  
Vol 9 (12) ◽  
pp. 1155-1167
Author(s):  
Sobia Kanwal ◽  
Tariq Mahmood
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Social Factors ◽  
Molecular Mechanisms ◽  
Public Health Problem ◽  
Pegylated Interferon ◽  
Host Factors ◽  
Interferon Α ◽  
Major Public Health Problem ◽  
Choice Of Treatment

AbstractHepatitis C virus is presently a major public health problem across the globe. The main objective in treating hepatitis C virus (HCV) infection is to achieve a sustained virological response (SVR). Interferon-α (IFN-α) and pegylated interferon (PegIFN) in combination with Ribavirin (RBV) are the choice of treatment nowadays against chronic hepatitis C. There are several mechanisms evolved by the hepatitis C virus that facilitate the persistence of virus and further lead the patient’s status as non responder. Various factors involved in patient’s lack ofresponse to the therapy include: (1) viral factors, (2) host factors, (3) molecular mechanisms related to the lack of response and (4) social factors. Herein we have made an attempt to summarize all the related predictors of drug resistance in one article so that the future polices can be planned to overcome this obstacle and potential therapies can be designed by considering these factors.

Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose

2013 ◽  
Vol 34 (10) ◽  
pp. 1522-1531 ◽  
Author(s):  
Yan Xu ◽  
Wenqian Qi ◽  
Xu Wang ◽  
Ping Zhao ◽  
Yonggui Zhang ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Cumulative Dose ◽  
Pegylated Interferon ◽  
Interferon Α

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

2007 ◽  
Vol 132 (4) ◽  
pp. 1270-1278 ◽  
Author(s):  
Christoph Sarrazin ◽  
Regine Rouzier ◽  
Frank Wagner ◽  
Nicole Forestier ◽  
Dominique Larrey ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Protease Inhibitor ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Genotype 1

scholarly journals A case of hepatitis C virus-associated liver cirrhosis with cryoglobulinemia, esophageal varices and ascites treated with pegylated interferon-α 2b and ribavirin

Kanzo ◽  
2011 ◽  
Vol 52 (3) ◽  
pp. 163-168
Author(s):  
Shin-ya Onohara ◽  
Kazufumi Dohmen ◽  
Hirofumi Tanaka ◽  
Masatora Haruno ◽  
Makoto Irie ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Esophageal Varices ◽  
Pegylated Interferon ◽  
Interferon Α

Prevalence and Distribution of Hepatitis C Virus in Iranian Drug User: Systematic Review and Meta-Analysis Study

2020 ◽  
Author(s):  
Alireza Najimi-Varzaneh ◽  
Mohammad Gholami-Fesharaki
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug User ◽  
Drug Users ◽  
Meta Analysis ◽  
Scientific Information ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Analysis Study ◽  
Hcv Prevalence

Context: Hepatitis C, as a major public health problem, has serious complications and drug users are the highest risk group for it.Objectives: As the importance of this subject, the current study has been done to estimate the pooled prevalence  and distribution of hepatitis c virus in Iranian Drug User.Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar and Web of Science and Iranian scientific information database (SID), Health. barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of HCV Iranian Drug User.Results: 227 records were identified by the electronic search, of which 62 studies were identified as relevant  papers which were meta-analyzed for the pooled HCV prevalence. Overall, prevalence of HCV  was 42.01 %( 36.83%-47.20%) in Iranian drug user.Conclusion: Our meta-analysis study showed that HCV prevalence is high in drug users in Iran. With respect to the high prevalence of Hepatitis C among Drug User, ongoing preventive actions for this group are recommended.

Sign in / Sign up

Export Citation Format

Share Document